Says 2026 to be year of growing impact for company. Says has “strong” cash position, with $1.9B as of the end of Q3 and an additional $1.75B in committed capital. Comments taken from 44th Annual JPMorgan Healthcare Conference.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines CEO presenting at JPMorgan healthcare conference
- Top 5 Trending Stocks by Unusual Trading Volume, 1/10/26
- Merck in talks to pay about $30B for Revolution Medicines, WSJ says
- STAT’s Adam Feuerstein says Revolution Medicines canceled meeting
- Video: Trump boosts Intel, Meta charges up nuclear power stocks